Sepracor News

How could that be? Investors only care about how much of the drug Vanda can sell, and study results that may be good enough for continued clinical testing and possible marketing approval don't guarantee a ...

Mechelen, Belgium; 30 June 2008 - Galapagos NV announces today that its service division BioFocus DPI will provide compound management and related services to Sepracor Inc.

The 495/MetroWest Corridor Partnership has given an award to Sepracor Inc. of Marlborough for its contributions to the region.

Serving as the premier event for healthcare facility industry professionals to exchange and explore new concepts, practices and solutions in effective and - [ more ] MAYFIELD VILLAGE, Ohio-- --Are you the ...

Jun 24, 2008 - Cubist Pharmaceuticals, Inc. today announced the appointment of Mark H.N. Corrigan, M.D., to its Board of Directors.

Main Category: Epilepsy Also Included In: Conferences Article Date: 21 Jun 2008 - 4:00 PDT Sepracor Inc.

The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Sepracor Inc said on Thursday late-stage studies of its experimental epilepsy treatment showed a significant reduction in partial seizures when the product was given along with other epilepsy drugs.

We see little that can be done to reaccelerate sales of Sepracor, Inc.'s sleeping pill Lunesta in the U.S. Thankfully, we are pleased to see management looking to move beyond Lunesta and expanding its ...

WASHINGTON - Medicare contractors are suspending a planned pay cut for Sepracor Inc's asthma drug Xopenex, which will also benefit oxygen suppliers Apria Healthcare Group Inc and Lincare Holdings ...

An executive vice president at drug maker Sepracor Inc. sold 5,500 shares of common stock, according to a Securities and Exchange Commission filing Thursday.

Tables: Buyers Sellers ALTHOUGH SHARES OF Sepracor have been weakening over the past year, the chief executive officer has taken a dose of his own medicine, snapping up $1 million of the drug maker's stock.

Marlborough-based pharmaceutical company Sepracor Inc. has completed its $50 million acquisition of Oryx Pharmaceuticals Inc.

GuruFocus News Filed Under: AAP , SEPR , EXR , MBI , JRT , Filed Under: AAP , SEPR , EXR , MBI , JRT , Filed Under: AAP , SEPR , EXR , MBI , JRT , Filed Under: AAP , SEPR , EXR , MBI , JRT , Filed Under: AAP , ...

Newton-based Northland Investment Corp. has sold 33 Locke Dr. in Marlborough to Janelon Trust for $7.15 million.

Drug stocks slipped in early action Thursday as shares of Sepracor Inc. lost ground on news that its chief financial officer was leaving the company. via MarketWatch

“Patients suffering from insomnia may have co-existing medical and psychiatric illnesses”

A new study found the use of a particular medication helped individuals suffering from insomnia and generalized anxiety disorder . via Psych Central News

“David has played a major role in creating a highly successful, fully integrated public pharmaceutical company, and his impact will have a lasting impression on Sepracor, its employees and shareholders for many years to come”

Sepracor Inc. today announced that David P. Southwell has notified the Company that he will resign as Executive Vice President, Chief Financial Officer as of May 20, 2008 to pursue other interests. via BioSpace

In the wide and varied family of the thousands and thousands of funds out there, the exchange-traded fund is one of the more consumer-friendly ones. via Fox News

“Patients suffering from insomnia may have co-existing medical and psychiatric illnesses”

LUNESTA Study Of Patients With Insomnia And Co-Morbid Generalized Anxiety Disorder Published In Archives Of General Psychiatry Main Category: Anxiety / Stress Also Included In: Psychology / Psychiatry Article ... via MediLexicon